AN AUTHORITATIVE RESOURCE FOR EVERYTHING ABOUT CANCER
All Articles
Colorectal Cancer at ASCO 2026: When to Stop Immunotherapy, How to Use BRAF-Targeted Therapy, and Why Exercise Belongs in the Treatment Plan
By Stacey A. Cohen, MD
Before discussing any of the specific advances from ASCO 2026, the single most important principle in colorectal cancer is straightforward: test all patients for microsatellite instability (MSI).
Colorectal Cancer at ASCO 2026: When to Stop Immunotherapy, How to Use BRAF-Targeted Therapy, and Why Exercise Belongs in the Treatment Plan
By Stacey A. Cohen, MD
Before discussing any of the specific advances from ASCO 2026, the single most important principle in colorectal cancer is straightforward: test all patients for microsatellite instability (MSI).
Colorectal Cancer at ASCO 2026: When to Stop Immunotherapy, How to Use BRAF-Targeted Therapy, and Why Exercise Belongs in the Treatment Plan
By Stacey A. Cohen, MD
Before discussing any of the specific advances from ASCO 2026, the single most important principle in colorectal cancer is straightforward: test all patients for microsatellite instability (MSI).
Prostate Cancer at ASCO 2026: Perioperative Intensification Changes the High-Risk Localized Landscape, PARP Inhibitors Move Earlier, and De-escalation Data Arrives
By Alexandra Sokolova, MD
ASCO 2026 brought multiple practice-influencing trials in prostate cancer spanning localized high-risk disease, metastatic hormone-sensitive disease, and de-escalation for exceptional responders.
Prostate Cancer at ASCO 2026: Perioperative Intensification Changes the High-Risk Localized Landscape, PARP Inhibitors Move Earlier, and De-escalation Data Arrives
By Alexandra Sokolova, MD
ASCO 2026 brought multiple practice-influencing trials in prostate cancer spanning localized high-risk disease, metastatic hormone-sensitive disease, and de-escalation for exceptional responders.
Prostate Cancer at ASCO 2026: Perioperative Intensification Changes the High-Risk Localized Landscape, PARP Inhibitors Move Earlier, and De-escalation Data Arrives
By Alexandra Sokolova, MD
ASCO 2026 brought multiple practice-influencing trials in prostate cancer spanning localized high-risk disease, metastatic hormone-sensitive disease, and de-escalation for exceptional responders.
Clinical Review of Cellular Therapies for Multiple Myeloma Part II: Toxicities of CAR-T for the Community and Rural Oncologist
By Adeel M Khan MD MPH MS; Aimaz Afrough, MD; Samer Al Hadidi, MD, MS; Sean Taasan, MD; Larry D Anderson Jr, MD, PhD
While ide-cel and cilta-cel are generally considered safe and have remarkable therapeutic impact for relapsed/refractory myeloma, both agents carry a broad and clinically significant toxicity burden that practitioners must recognize and actively surveil.
Clinical Review of Cellular Therapies for Multiple Myeloma Part II: Toxicities of CAR-T for the Community and Rural Oncologist
By Adeel M Khan MD MPH MS; Aimaz Afrough, MD; Samer Al Hadidi, MD, MS; Sean Taasan, MD; Larry D Anderson Jr, MD, PhD
While ide-cel and cilta-cel are generally considered safe and have remarkable therapeutic impact for relapsed/refractory myeloma, both agents carry a broad and clinically significant toxicity burden that practitioners must recognize and actively surveil.
Clinical Review of Cellular Therapies for Multiple Myeloma Part II: Toxicities of CAR-T for the Community and Rural Oncologist
By Adeel M Khan MD MPH MS; Aimaz Afrough, MD; Samer Al Hadidi, MD, MS; Sean Taasan, MD; Larry D Anderson Jr, MD, PhD
While ide-cel and cilta-cel are generally considered safe and have remarkable therapeutic impact for relapsed/refractory myeloma, both agents carry a broad and clinically significant toxicity burden that practitioners must recognize and actively surveil.
Clinical Review of Cellular Therapies for Multiple Myeloma Part I: A Primer on CAR-T for the Community and Rural Oncologist
By Adeel M Khan MD MPH MS; Aimaz Afrough, MD; Samer Al Hadidi, MD, MS; Sean Taasan, MD; Larry D Anderson Jr, MD, PhD
Ide-cel was the first anti-BCMA CAR-T product approved by the FDA in March 2021, employing a single anti-BCMA single-chain variable fragment.
Clinical Review of Cellular Therapies for Multiple Myeloma Part I: A Primer on CAR-T for the Community and Rural Oncologist
By Adeel M Khan MD MPH MS; Aimaz Afrough, MD; Samer Al Hadidi, MD, MS; Sean Taasan, MD; Larry D Anderson Jr, MD, PhD
Ide-cel was the first anti-BCMA CAR-T product approved by the FDA in March 2021, employing a single anti-BCMA single-chain variable fragment.
Clinical Review of Cellular Therapies for Multiple Myeloma Part I: A Primer on CAR-T for the Community and Rural Oncologist
By Adeel M Khan MD MPH MS; Aimaz Afrough, MD; Samer Al Hadidi, MD, MS; Sean Taasan, MD; Larry D Anderson Jr, MD, PhD
Ide-cel was the first anti-BCMA CAR-T product approved by the FDA in March 2021, employing a single anti-BCMA single-chain variable fragment.
Daraxonrasib: The New Pancreatic Cancer Drug Patients Can Access Now through Clinical Trial Showing Promising Results
By Krutika Gohil, MD
Results of the RASolute 302 clinical trial show Daraxonrasib nearly doubles survival with fewer side effects compared to chemotherapy for pancreatic cancer patients.
Daraxonrasib: The New Pancreatic Cancer Drug Patients Can Access Now through Clinical Trial Showing Promising Results
By Krutika Gohil, MD
Results of the RASolute 302 clinical trial show Daraxonrasib nearly doubles survival with fewer side effects compared to chemotherapy for pancreatic cancer patients.
Daraxonrasib: The New Pancreatic Cancer Drug Patients Can Access Now through Clinical Trial Showing Promising Results
By Krutika Gohil, MD
Results of the RASolute 302 clinical trial show Daraxonrasib nearly doubles survival with fewer side effects compared to chemotherapy for pancreatic cancer patients.
Multiple Myeloma and Plasma Cell Disorders in 2026: Bispecifics Move Earlier, MRD Guides Duration, and Amyloidosis Finally Has a Target
By Laahn Foster, MD
The data presented at ASCO 2026 provide more clarity on where bispecifics fit in the treatment sequence, how long to use them, and whether they can be used as an earlier intervention.
Multiple Myeloma and Plasma Cell Disorders in 2026: Bispecifics Move Earlier, MRD Guides Duration, and Amyloidosis Finally Has a Target
By Laahn Foster, MD
The data presented at ASCO 2026 provide more clarity on where bispecifics fit in the treatment sequence, how long to use them, and whether they can be used as an earlier intervention.
Multiple Myeloma and Plasma Cell Disorders in 2026: Bispecifics Move Earlier, MRD Guides Duration, and Amyloidosis Finally Has a Target
By Laahn Foster, MD
The data presented at ASCO 2026 provide more clarity on where bispecifics fit in the treatment sequence, how long to use them, and whether they can be used as an earlier intervention.
Relapsed and Refractory DLBCL in 2026: More Options Than Ever, and Three Questions That Actually Matter
By Timothy Fenske, MD
Four of the five randomized R/R DLBCL trials showing overall survival benefit have come in the last four years. Dr. Timothy Fenske maps the 2026 options and the three questions that actually guide treatment selection.
Relapsed and Refractory DLBCL in 2026: More Options Than Ever, and Three Questions That Actually Matter
By Timothy Fenske, MD
Four of the five randomized R/R DLBCL trials showing overall survival benefit have come in the last four years. Dr. Timothy Fenske maps the 2026 options and the three questions that actually guide treatment selection.
Relapsed and Refractory DLBCL in 2026: More Options Than Ever, and Three Questions That Actually Matter
By Timothy Fenske, MD
Four of the five randomized R/R DLBCL trials showing overall survival benefit have come in the last four years. Dr. Timothy Fenske maps the 2026 options and the three questions that actually guide treatment selection.
Rural Cancer Care and the Dollar Sign on Your Diagnosis
By Ariana Sutherland
A stage 4 breast cancer patient in Juneau had no local oncologist and spent thousands flying to Seattle for care. Her story puts a human face on rural cancer care's structural failures — and what it would take to fix them.
Rural Cancer Care and the Dollar Sign on Your Diagnosis
By Ariana Sutherland
A stage 4 breast cancer patient in Juneau had no local oncologist and spent thousands flying to Seattle for care. Her story puts a human face on rural cancer care's structural failures — and what it would take to fix them.
Rural Cancer Care and the Dollar Sign on Your Diagnosis
By Ariana Sutherland
A stage 4 breast cancer patient in Juneau had no local oncologist and spent thousands flying to Seattle for care. Her story puts a human face on rural cancer care's structural failures — and what it would take to fix them.
Daraxonrasib and the RASolute 302 Trial: A Paradigm Shift in the RAS Targeting Era and Management of Pancreatic Cancer
By Meghana Singh, MD; Ibrahim Halil Sahin, MD
For the first time, a targeted therapy has doubled overall survival in second-line metastatic pancreatic cancer. Two oncologists break down the RASolute 302 trial and what daraxonrasib means for the field.
Daraxonrasib and the RASolute 302 Trial: A Paradigm Shift in the RAS Targeting Era and Management of Pancreatic Cancer
By Meghana Singh, MD; Ibrahim Halil Sahin, MD
For the first time, a targeted therapy has doubled overall survival in second-line metastatic pancreatic cancer. Two oncologists break down the RASolute 302 trial and what daraxonrasib means for the field.
Daraxonrasib and the RASolute 302 Trial: A Paradigm Shift in the RAS Targeting Era and Management of Pancreatic Cancer
By Meghana Singh, MD; Ibrahim Halil Sahin, MD
For the first time, a targeted therapy has doubled overall survival in second-line metastatic pancreatic cancer. Two oncologists break down the RASolute 302 trial and what daraxonrasib means for the field.
Next-Generation KRAS Inhibitors in NSCLC: A Pipeline So Active It's Hard to Keep Up
By Robert Chun-Hao Hsu, MD
KRAS was considered undruggable for decades. The protein's smooth, shallow surface offered no obvious pocket for small molecule binding. Its extremely high affinity for GTP/GDP made competitive inhibition impractical.
Next-Generation KRAS Inhibitors in NSCLC: A Pipeline So Active It's Hard to Keep Up
By Robert Chun-Hao Hsu, MD
KRAS was considered undruggable for decades. The protein's smooth, shallow surface offered no obvious pocket for small molecule binding. Its extremely high affinity for GTP/GDP made competitive inhibition impractical.
Next-Generation KRAS Inhibitors in NSCLC: A Pipeline So Active It's Hard to Keep Up
By Robert Chun-Hao Hsu, MD
KRAS was considered undruggable for decades. The protein's smooth, shallow surface offered no obvious pocket for small molecule binding. Its extremely high affinity for GTP/GDP made competitive inhibition impractical.